What is the 13F Pro Quality Score for SYK?

13F Pro ranks STRYKER CORP (SYK) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SYK's current score at https://13fpro.ai/research/SYK (free sign-up required for the full ranking).

Which hedge funds own the most SYK stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of SYK include BlackRock,, VANGUARD CAPITAL MANAGEMENT, GREENLEAF. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/SYK as soon as new 13F filings post.

Where does 13F Pro source SYK data?

All STRYKER CORP fundamentals and ownership data come directly from SEC EDGAR. STRYKER CORP files with the SEC under CIK 310764. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SYK in?

STRYKER CORP (SYK) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives SYK's revenue?

Per STRYKER CORP's latest 10-Q filed with the SEC on 2026-05-11, the biggest revenue drivers are: MedSurg and Neurotechnology ($3,207M, +5.0% YoY); Orthopaedics ($2,813M, +0.1% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/research/SYK.

What are SYK's largest expenses?

STRYKER CORP's latest 10-Q reports these as the largest expense items: Cost of sales ($2,210M, +4.1% YoY); Selling, general and administrative expenses ($2,281M, -0.8% YoY); Research, development and engineering expenses ($413M, +2.0% YoY). Sourced directly from SEC EDGAR filing text for Q1 FY2026 (quarter ended March 31, 2026).

How often is SYK research updated on 13F Pro?

SYK's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

STRYKER CORP(SYK)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 310764 SYK stock profile & AI dashboard →

13F Pro Quality Score

69.8/100

Rank #347 of 2,879 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

64.6/100

Profitability

70.0/100

Balance Sheet

77.1/100

Earnings Quality

48.4/100

Free Cash Flow

67.0/100

Institutional Flow

37.9/100

Revenue Scale

94.0/100

Dilution Risk

57.7/100

SYK Stock Analysis & AI Quality Score

AI stock analysis and institutional research for STRYKER CORP (SYK), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SYK at 69.8/100 on a 32-signal composite quality model, placing it at rank #347 of 2,879 stocks — the top 25% of the AI-ranked universe. SYK scores in the top quartile across revenue scale (94.0), balance sheet strength (77.1). Areas of concern include institutional flow (37.9), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), STRYKER CORP reports quarterly revenue of $6.0B, net income of $745.0M, an operating margin of 15.6%. Top institutional holders of SYK by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, GREENLEAF, based on the most recent SEC filings. SYK trades on the NYSE exchange and files with the SEC under CIK 310764. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SYK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for STRYKER CORP directly from SEC EDGAR. STRYKER CORP's 13F Pro composite quality score has ranged between 8 and 74 since 2021, currently 69.8 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about STRYKER CORP

Quirks, history, and lore behind SYK — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · large-cap · listed on NYSE · headquartered in Michigan.
2
The Numbers
Annual revenue around $20 billion, with products sold in over 75 countries — if you've ever been wheeled into an OR, there's a decent chance their gear came along for the ride.
3
The History
Founded in 1941 by an orthopedic surgeon who wanted better tools for his patients — because sometimes the best way to fix healthcare is to literally build the device yourself.
4
The Secret
They don't make pills or run hospitals — they make the implants, surgical robots, and hospital beds that quietly dominate operating rooms and recovery floors worldwide.
5
The Lore
Their Mako robotic surgery system has been used in hundreds of thousands of procedures, and they've spent billions snapping up medical device rivals to stay ahead of the scalpel curve.
6
The Giveaway
An orthopedic surgeon named Homer started it in Kalamazoo, and today their hip and knee replacements are keeping Baby Boomers on the dance floor well past their expiration date.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving SYK's Business? Latest 10-Q Breakdown

AI-extracted from STRYKER CORP's 10-Q filed 2026-05-11 — Q1 FY2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Stryker reported Q1 2026 net sales of $6.0B (+2.6% YoY), but adjusted operating margin contracted 180 bps to 21.1% due to cybersecurity incident impacts and manufacturing cost pressures.

Biggest Revenue Drivers

Total revenue: $6,020M+2.6% YoY

MedSurg and Neurotechnology$3,207M+5.0% YoY

Higher shipments across Instruments and Vascular businesses; Vascular grew 27.5% driven by Inari acquisition integration

Orthopaedics$2,813M+0.1% YoY

Organic growth of 4.1% in constant currency offset by 5.9% divestiture impact from Spinal Implants sale

Largest Expense Items

Cost of sales$2,210M+4.1% YoY

Higher manufacturing and supply chain costs due to idle production time from cybersecurity incident

Selling, general and administrative expenses$2,281M-0.8% YoY

Lower acquisition and integration charges; 2025 included $139M in Inari stock compensation vesting

Research, development and engineering expenses$413M+2.0% YoY

Expenses as percentage of sales remained flat at 6.9%

Amortization of intangible assets$180M+7.8% YoY

Intangible amortization from Inari acquisition and other recent acquisitions

Watch Items from the Filing

Cybersecurity incident on March 11, 2026 caused material disruption to operations, including idle production time impacting Q1 gross margin by ~200 bps. Company's investigation remains ongoing with potential for further financial and reputational impacts.
Spinal Implants divestiture (sold April 2025) resulted in 98.9% revenue decline YoY; $269M deferred consideration receivable from Viscogliosi Brothers creates collection risk exposure.
Adjusted net earnings per diluted share declined 8.5% YoY to $2.60 despite 2.6% reported revenue growth, indicating margin compression and rising integration costs.
Inari acquisition (February 2025, $4.8B) integration ongoing; Vascular segment grew 27.5% but contributed to 2.7% divestiture impact in MedSurg segment offsetting organic growth.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$6.0B

Net Income

Q1 2026

$745.0M

Free Cash Flow

Q1 2026

$415.0M

Operating Margin

Q1 2026

15.6%

D/E Ratio

Q1 2026

0.64

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+11.2% YoY

$25.12BFY 2025

FY22 $18.45BFY23 $20.50BFY24 $22.59BFY25 $25.12B

Net Income

+8.5% YoY

$3.25BFY 2025

FY22 $2.36BFY23 $3.17BFY24 $2.99BFY25 $3.25B

Operating Income

+32.5% YoY

$4.89BFY 2025

FY22 $2.84BFY23 $3.89BFY24 $3.69BFY25 $4.89B

EPS (Diluted)

+8.2% YoY

$8.40FY 2025

FY22 $6.17FY23 $8.25FY24 $7.76FY25 $8.40

Total Assets

+11.3% YoY

$47.84BFY 2025

FY22 $36.88BFY23 $39.91BFY24 $42.97BFY25 $47.84B

Total Debt

+16.6% YoY

$15.86BFY 2025

FY22 $13.05BFY23 $12.99BFY24 $13.60BFY25 $15.86B

Op. Cash Flow

+18.9% YoY

$5.04BFY 2025

FY22 $2.62BFY23 $3.71BFY24 $4.24BFY25 $5.04B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$25.12B +11.2%	$22.59B +10.2%	$20.50B +11.1%	$18.45B +7.8%	$17.11B +19.2%	$14.35B
Net Income	$3.25B +8.5%	$2.99B -5.4%	$3.17B +34.2%	$2.36B +18.3%	$1.99B +24.7%	$1.60B
Operating Income	$4.89B +32.5%	$3.69B -5.1%	$3.89B +36.9%	$2.84B +9.9%	$2.58B +16.2%	$2.22B
EPS (Diluted)	$8.40 +8.2%	$7.76 -5.9%	$8.25 +33.7%	$6.17 +18.4%	$5.21 +24.0%	$4.20
Total Assets	$47.84B +11.3%	$42.97B +7.7%	$39.91B +8.2%	$36.88B +6.5%	$34.63B +0.9%	$34.33B
Total Debt	$15.86B +16.6%	$13.60B +4.6%	$12.99B -0.4%	$13.05B +4.6%	$12.48B -10.8%	$13.99B
Operating Cash Flow	$5.04B +18.9%	$4.24B +14.3%	$3.71B +41.4%	$2.62B -19.6%	$3.26B -0.4%	$3.28B

AI Insight: SYK Financial Trends

Stryker's Q4 2025 operating income surged to $1,804M on $7,171M revenue, but Q1 2026 shows the typical seasonal step-down with debt declining to $14,723M.

• Revenue grew 11.4% year-over-year from Q1 2025 ($5,866M) to Q4 2025 ($7,171M), with Q1 2026 at $6,020M up 2.6% vs Q1 2025.

• Operating income in Q4 2025 reached $1,804M, nearly triple Q4 2024's $581M, signaling a significant margin improvement quarter-over-quarter.

• Total debt rose sharply from $12,222M in Q2 2024 to $16,781M in Q1 2025, but has since declined to $14,723M in Q1 2026.

• Operating cash flow hit $2,143M in Q4 2025, the strongest quarter in the dataset, up from $1,931M in Q4 2024.

⚠ Q1 2026 operating cash flow fell sharply to $581M from Q4 2025's $2,143M — though seasonal, it warrants monitoring for recovery trajectory.

⚠ Total debt remains elevated at $14,723M in Q1 2026 versus $12,222M in Q2 2024 — a 20% increase with equity data unavailable to assess leverage fully.

⚠ Net income dipped to $745M in Q1 2026 from $884M in Q2 2025 — track whether margin pressure persists into Q2 2026.

AI Insight: SYK Ratio Trends

Stryker's Q4 2025 operating margin spike to 25.2% appears one-off; Q1 2026 snaps back to 15.6%, with ROIC falling sharply from 45.5% to 25.4%.

• Operating margin swung from a trough of 9.0% in Q4 2024 to a peak of 25.2% in Q4 2025, then retreated to 15.6% in Q1 2026.

• ROIC has trended well below mid-2024 levels: 34.4% in Q2 2024 vs. 25.4% in Q1 2026, despite the Q4 2025 spike.

• Net profit margin compressed from 15.2% in Q2–Q3 2024 to 12.4% in Q1 2026, signaling modest but persistent profitability pressure.

• ROA followed a similar pattern: 8.4% in Q2 2024 declining to 6.4% in Q1 2026, consistent with lower capital efficiency.

⚠ Q4 2025's 25.2% operating margin and 45.5% ROIC look anomalous — identify whether a one-time gain or true efficiency improvement drove the spike.

⚠ Q4 2024 margin collapse to 9.0% operating / 17.1% ROIC warrants monitoring for recurrence of similar cost or write-down events.

⚠ TTM ROIC of 33.9% is flattered by the Q4 2025 outlier; underlying run-rate ROIC appears closer to 25–27%, a meaningful step-down from 2024.

Get alerted when SYK's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for STRYKER CORP including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SYK

BlackRock, Inc.
$9.1B27,602,049 sh
VANGUARD CAPITAL MANAGEMENT LLC
$7.4B22,383,181 sh
GREENLEAF TRUST
$5.2B15,938,070 sh
STATE STREET CORP
$5.1B15,349,165 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$2.7B8,334,244 sh
WELLINGTON MANAGEMENT GROUP LLP
$2.7B8,121,707 sh
GEODE CAPITAL MANAGEMENT, LLC
$2.5B7,748,294 sh
ALLIANCEBERNSTEIN L.P.
$2.1B6,052,989 sh
MORGAN STANLEY
$2.1B6,297,555 sh
Capital Research Global Investors
$1.8B5,612,389 sh

Fund	Value	Shares
BlackRock, Inc.	$9.1B	27,602,049
VANGUARD CAPITAL MANAGEMENT LLC	$7.4B	22,383,181
GREENLEAF TRUST	$5.2B	15,938,070
STATE STREET CORP	$5.1B	15,349,165
VANGUARD PORTFOLIO MANAGEMENT LLC	$2.7B	8,334,244
WELLINGTON MANAGEMENT GROUP LLP	$2.7B	8,121,707
GEODE CAPITAL MANAGEMENT, LLC	$2.5B	7,748,294
ALLIANCEBERNSTEIN L.P.	$2.1B	6,052,989
MORGAN STANLEY	$2.1B	6,297,555
Capital Research Global Investors	$1.8B	5,612,389

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SYK on your watchlist

Track score changes the day STRYKER CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SYK a good stock to buy?

13F Pro's AI-powered analysis of STRYKER CORP (SYK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SYK are available on the SYK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SYK?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SYK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of STRYKER CORP's investment landscape.